

BMJ Paediatrics Open

BMJ Paediatrics Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Paediatrics Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjpaedsopen.bmj.com>).

If you have any questions on BMJ Paediatrics Open's open peer review process please email info.bmjpo@bmj.com

BMJ Paediatrics Open

Healthcare Utilisation in Children with SMA Type 1 Treated with Nusinersen: a single centre retrospective audit

Journal:	<i>BMJ Paediatrics Open</i>
Manuscript ID	bmjpo-2019-000572
Article Type:	Original research
Date Submitted by the Author:	23-Aug-2019
Complete List of Authors:	<p>Ali, Imran; University Hospitals of North Midlands NHS Trust, Paediatric Respiratory Medicine</p> <p>Gilchrist, Francis; University Hospitals of North Midlands NHS Trust, Paediatric Respiratory Medicine; Keele University, Institute of Applied Clinical Science</p> <p>Carroll, William; University Hospitals of North Midlands NHS Trust, Paediatric Respiratory Medicine; Keele University, Institute of Applied Clinical Services</p> <p>Alexander, John; University Hospitals of North Midlands NHS Trust, Paediatric Respiratory Medicine</p> <p>Clayton, Sadie ; University Hospitals of North Midlands NHS Trust, Paediatric Respiratory Medicine</p> <p>Kulshrestha, Richa; Robert Jones and Agnes Hunt Orthopaedic and District Hospital NHS Trust</p> <p>Willis, Tracey; Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust</p> <p>Samuels, Martin; University Hospitals of North Midlands NHS Trust, Paediatric Respiratory Medicine</p>
Keywords:	Respiratory, Neuromuscular, Neurodisability, Costing

SCHOLARONE™
Manuscripts

Healthcare Utilisation in Children with SMA Type 1 Treated with Nusinersen: a single centre retrospective audit

Imran Ali¹ MB BS

Paediatric Trainee

Francis Gilchrist¹

Consultant Respiratory Paediatrician

Will Carroll¹

Consultant Paediatrician

John Alexander¹

Consultant Paediatrician

Sadie Clayton¹

Consultant Nurse

Richa Kulshrestha²

Consultant Paediatric Neurologist

Tracey Willis²

Consultant Paediatric Neurologist

Martin Samuels¹ MD FRCPCH

Consultant Respiratory Paediatrician

Address: ¹ Children's Centre

Royal Stoke University Hospital

Stoke-on-Trent

Staffs

ST4 6QG

² The Robert Jones & Agnes Hut Orthopaedic Hospital

Oswestry

Shropshire

SY10 7AG

Corresponding Author: Dr MP Samuels

GMC Reg No 2732178

Phone no: 07710 673965

Email: martin.samuels@uhnm.nhs.uk or samuels@doctors.org.uk

Word Count: 1599 (excluding references)

Healthcare Utilisation in Children with SMA Type 1 Treated with Nusinersen

Abstract:

Background: Nusinersen has been used to treat spinal muscular atrophy type 1 (SMA1) in the UK since 2017. While initial trials showed neuromuscular benefit from treating SMA1, there is little information on the respiratory effects of nusinersen. We aimed to look at the respiratory care, hospital utilisation and associated costs in newly treated SMA1.

Methods: We reviewed the medical records of all children within the West Midlands with SMA1 treated with nusinersen at Royal Stoke University Hospital. Baseline demographics and hospital admission data were collected including: the reason for admission, total hospital days, HDU days, PICU days, days intubated, discharge diagnosis, doses of nusinersen and treatment complications.

Results: Eleven children (six girls) received nusinersen between May 2017 and April 2019. Their median (range) age was 29 (7–97) months. The median (range) number of nusinersen doses per child was 6 (4-8). All children were receiving long-term ventilatory support; this was non-invasive BiPAP in nine and tracheostomy ventilation in two. The total number of hospital days since diagnosis was 1101 with a median (range) of 118 (7-235) days per child. This included general paediatric ward days 0 (0-63), HDU 79 (7-173) days and PICU 13 (0-109) days per child. This equated to a median (range) of 20 (2 - 72) % of their life in hospital. The estimated cost of this care was £2.2M.

Conclusion: Patients with SMA1 treated with nusinersen spend a considerable proportion of their early life in hospital. Parents should be counselled accordingly. This healthcare utilisation has a significant cost implication.

Background

Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder characterised by progressive muscular atrophy and weakness.(1) It has an incidence of 1 in 11,000 live births.(2) There are various subgroups of SMA classified clinically, with SMA type 1 (SMA1) accounting for approximately 60% of cases, and carrying the worst prognosis.(3) Until recently, SMA1 was the commonest genetic disease resulting in death in infancy.(4) Affected children usually present with symptoms before six months of age and historically died from respiratory failure by the age of two years.(5)

SMA1 is caused by the homozygous deletion or mutation of the survival motor neuron 1 (*SMN1*) gene. This results in reduced expression of the SMN protein, which is essential for the survival of motor neurones in the spinal cord and brain stem.(6) Inadequate expression of SMN protein causes degeneration of the motor neurone which in turn causes the associated muscles to atrophy. Humans have a variable number of copies of a second gene, *SMN2* which also encodes for SMN protein.(6) However, *SMN2* is a poor back-up gene and therefore leads to a truncated form of the protein, mostly degraded and a small amount, approximately 10%, of functional full length protein, as a result of aberrant RNA splicing. Approximately 80% of infants with SMA1 have only 1 or 2 copies of *SMN2* and are therefore unable to produce enough functional SMN protein to support normal muscle development.

Nusinersen is an antisense oligonucleotide which works by binding to the *SMN2* mRNA and in order to be effective it must be delivered into the cerebrospinal fluid. This binding modifies splicing of the *SMN2* gene to promote increased production of functional SMN protein.(7) Treatment with nusinersen has the potential to transform prognosis for these children offering hope of treatment for the first time. The drug has been used in the UK since early 2017. The drug costs £450,000 in the first year and £225,000 per annum subsequently and for patients beginning this from before November 2018, the manufacturer provided this free through an Expanded Access Programme.(8) NHSE provides an administration cost, but not the other aspects of care for these patients. While randomised controlled trials showed nusinersen improved motor function and development,(7) it is unclear whether the respiratory consequences produce similar benefits and thus the demands of treatment for families and health economies is yet to be established.

Royal Stoke University Hospital (RSUH) is a regional centre for nusinersen administration and in March 2019 had the second largest cohort of patients in the UK. Before agreeing to act as a regional centre for nusinersen delivery, we carefully considered the potential effects on children, their families and

1
2
3 other healthcare services. However, data were lacking making counselling of families and planning of
4 service provision difficult. We have carefully monitored healthcare utilisation of SMA1 children
5 treated with nusinersen. The aim of this article is to report the data on service utilisation for these
6 children to assist families and healthcare professionals.
7
8
9

10 **Methods**

11
12 Patients treated with intrathecal nusinersen at RSUH were identified from a local database. The paper
13 notes and electronic clinical records were reviewed to collect relevant data from RSUH and the child's
14 referring hospital. This included baseline demographics, age at diagnosis, details of ventilatory
15 support, feeding support, number of nusinersen doses, complications following administration and
16 details of all hospital admissions. Hospital admission data included: duration of admission, number of
17 HDU days, PICU days and intubated days. Nusinersen usually necessitated admission for one night for
18 the first dose only.
19
20
21
22
23
24
25

26 **Patient and public involvement**

27
28 No patients were involved in setting the research question or the outcome measures. The results of
29 this study will be disseminated to patient groups such as SMA UK and MD UK.
30
31

32 **Approval and ethical considerations**

33
34 The HRA decision tool (<http://www.hra-decisiontools.org.uk/research>) confirmed this project was
35 audit not research and so ethical approval was not sought. The audit was approved by the
36 departmental governance lead.
37
38
39
40

41 **Results**

42
43 We identified eleven children (six girls) who received nusinersen through the Expanded Access
44 Program at RSUH between May 2017 April 2019. Parents of a 12th child declined nusinersen and the
45 child died at 3 months of age. The median (range) number of nusinersen doses was 6 (4-8). Nine
46 children received non-invasive BiPAP and two children were ventilated via tracheostomy. Two patients
47 (including one on tracheostomy ventilation) have died suddenly at home from presumed mucous
48 plugs, while one other patient had a cardiorespiratory arrest and has suffered hypoxic brain injury.
49
50
51
52
53

54 Duration and location of admissions

55
56 In 24 months, the 11 children had spent a total of 1101 days in hospital. The median (range) per child
57 was 84 (7-235) days. This included a total of 91 general paediatric ward days, 762 HDU days and 248
58 PICU days. The median (range) per child was 0 (0-63) ward days, 79 (7-173) HDU days and 13 (0-109)
59
60

PICU days. Three children were responsible for all admissions to the general paediatric ward which occurred at their local hospital. Three children had not been admitted to PICU. Of the eight children that had, six had been intubated for a total of 38 days. The median (range) proportion of life spent in hospital was 20% (2% - 72%). This was very variable with four children spending $\leq 10\%$, four 10-35% and three $>35\%$.

Reason for admission

The median age (range) for initiation of nusinersen was 35 (2 – 372) weeks. Since initiation of nusinersen the eleven children had a total of 107 hospital admissions with a median (range) per child of 11 (1-25). The commonest reason for admission was lower respiratory tract infection (n=42), followed by elective administration of intrathecal nusinersen (n=38). There were seven admissions for gastrointestinal issues, six for an elective sleep study, five for aspiration pneumonia, four for increased secretions or airway issues and three for optimisation of ventilatory support.

Trends in admissions

Children in our cohort had the greatest requirement for hospital admission in the first 6 months following nusinersen initiation (see Figure 1). Much of this effect is driven by a tendency for children to have a long first admission (see Figure 2). Subsequent admissions tend to be shorter. The total number of hospital days for the children's first admission was 426 days with a median (range) of 20 (1 -235) days per child.

Cost implications and impact on local services

A total of 762 HDU days and 248 PICU days were required by the 11 children in our cohort over two years. This equates to 2.8 days in HDU and 0.93 days in PICU per child each month. RSUH has six HDU (four acute HDU beds and two long term ventilation) and eight PICU beds. The children therefore occupied 17% of the total HDU capacity and 4.2% of the PICU capacity over the study period. Based on current estimates of £1626 per day for a HDU bed and £1785 to £3784 for a PICU bed (depending on the level of care), the additional cost of these HDU/PICU days is £2.2M.(9) This is separate to the cost of the nusinersen and its administration.

Prior to the introduction of nusinersen, patients with SMA1 were generally not admitted for in-patient care, as they were managed within the community and local children's hospices.

Discussion

1
2
3 This is the first study which accurately reports the healthcare utilisation of a cohort of children treated
4 with nusinersen. This information is vital for those planning healthcare services. In the first two years
5 after diagnosis, these children spend one fifth of their early life in hospital. This places a significant
6 burden on parents and families and they should be counselled accordingly. There is a considerable
7 impact on hospital services, particularly on high dependency and PICU. This involves a substantial extra
8 resource, in addition to the direct cost of the nusinersen. Reassuringly, the number of hospital days
9 has reduced as the child gets older.

10
11
12 In addition to the costs associated with in-patient care, these children frequently require care
13 packages which incur additional community costs. These costs are likely to continue throughout the
14 child's life. NHSE has decided to fund nusinersen and so the numbers of SMA1 patients surviving and
15 treated with nusinersen will increase, along with the demand on critical care and community services.
16 Currently there is no ring-fenced funding for the health needs of SMA1 patients receiving nusinersen
17 and this is something that must be explored to provide optimal care for these patient without affecting
18 that of other children requiring critical care services.

19
20
21 We acknowledge the limitations of this study. It includes only eleven patients treated at one centre,
22 although this is the second largest in the UK. The retrospective nature of the study may have
23 introduced bias and we did not adjust for potential confounding factors such as socioeconomic status
24 and co-morbidities. Estimates of the financial burden have concentrated on in-patient rather than
25 community costs and will therefore be an underestimate.

26
27
28 There is a fall in the number of days spent in hospital. This may be explained by: i) a true improvement
29 in the respiratory muscle strength of these children over time, or ii) a gradual improvement in the
30 medical care provided, or iii) an improved ability of these families to cope with their medical conditions
31 at home and in their own community or iv) deaths within our cohort. Whilst an important
32 consideration, mortality alone seems unlikely to be the sole driver of this effect as only two children
33 within the cohort have died at 12 and 16 months respectively.

34
35
36 It may be a function of all of these and we hope that the first three factors will continue to operate.

37 38 39 Conclusion

40
41
42 While the improved prognosis and life expectancy associated with nusinersen treatment is exciting
43 for children with SMA1 and their families, we remain unsure that the respiratory benefits are as great
44 as that shown for the neurological improvement in the preliminary trials. This study has highlighted
45 that such children will spend a significant amount of their life in hospital, particularly in the first
46 months after diagnosis. This places a significant burden on families and on the NHS in general. The

1
2
3 long term outcome for these children is still unknown but the trend for a reduction in hospital days as
4 the child gets older may be reassuring. Further prospective studies with larger patient numbers are
5 required to more accurately quantify the health care utilisation by these children and the associated
6 financial burden.
7
8
9

10
11
12
13
14
15
16 What is already known on this topic:

17
18 Nusinersen improves prognosis and life expectancy in children with SMA 1.

19
20 Infants are now surviving with immense dependency on healthcare services.

21
22 NICE has just agreed to fund this new treatment (May 2019).
23
24
25

26
27
28 What this study adds:

29
30 Children with SMA1 who receive Nusinersen have significant ongoing medical costs in addition to the
31 cost of the drugs received.
32
33

34
35 On average this currently is more than £100,000 per patient per year in the first two years of follow
36 up.
37

38
39 Associated healthcare costs reduce as time progresses and are less in the second year of life.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Pearn J. Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. *Journal of medical genetics*. 1978 Dec;15(6):409–13.
2. Kolb SJ, Kissel JT. Spinal Muscular Atrophy. *Neurologic clinics*. 2015 Nov;33(4):831–46.
3. Verhaart IEC, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S, Jones CC, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. *Orphanet journal of rare diseases*. 2017 Jul 4;12(1):124–124.
4. Wirth B. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). *Hum Mutat*. 2000;15(3):228–37.
5. Park HB, Lee SM, Lee JS, Park MS, Park KI, Namgung R, et al. Survival analysis of spinal muscular atrophy type I. *Korean journal of pediatrics*. 2010 Nov;53(11):965–70.
6. Burghes AHM, Beattie CE. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? *Nature reviews Neuroscience*. 2009 Aug;10(8):597–609.
7. Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. *Lancet*. 2016 Dec 17;388(10063):3017–26.
8. NICE project team. Nusinersen for treating spinal muscular atrophy [Internet]. NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE; 2018 [cited 2019 Nov 1]. Available from: <https://www.nice.org.uk/guidance/gid-ta10281/documents/appraisal-consultation-document>
9. NHS improvement. National cost collection guidance 2019 [Internet]. NHS; 2019 [cited 2019 Apr 2]. Available from: https://improvement.nhs.uk/documents/4883/National_cost_collections_19.pdf

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure Legend

Figure 1: Total hospital days per month spent by children following commencement on nusinersen.

Figure 2: Median length of hospital stay per admission for all children.


Confidential: For Review Only

Footnotes

Contributors: MS and JA originated the design of the study. IA collected the data and drafted the manuscript. FG and MS supervised the writing. IA, FG, WC, MS, JA, SC, TW and RK revised each draft for important intellectual content. All authors read and approved the final manuscript. MS had primary responsibility for the final content and is the guarantor. The corresponding author (MS) attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.


Transparency: The manuscript's guarantor (MS) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



254x190mm (96 x 96 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



254x190mm (96 x 96 DPI)

BMJ Paediatrics Open

Healthcare Utilisation in Children with SMA Type 1 Treated with Nusinersen: a single centre retrospective review

Journal:	<i>BMJ Paediatrics Open</i>
Manuscript ID	bmjpo-2019-000572.R1
Article Type:	Original research
Date Submitted by the Author:	07-Oct-2019
Complete List of Authors:	<p>Ali, Imran; University Hospitals of North Midlands NHS Trust, Paediatric Respiratory Medicine</p> <p>Gilchrist, Francis; University Hospitals of North Midlands NHS Trust, Paediatric Respiratory Medicine; Keele University, Institute of Applied Clinical Science</p> <p>Carroll, William; University Hospitals of North Midlands NHS Trust, Paediatric Respiratory Medicine; Keele University, Institute of Applied Clinical Services</p> <p>Alexander, John; University Hospitals of North Midlands NHS Trust, Paediatric Respiratory Medicine</p> <p>Clayton, Sadie ; University Hospitals of North Midlands NHS Trust, Paediatric Respiratory Medicine</p> <p>Kulshrestha, Richa; Robert Jones and Agnes Hunt Orthopaedic and District Hospital NHS Trust</p> <p>Willis, Tracey; Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust</p> <p>Samuels, Martin; University Hospitals of North Midlands NHS Trust, Paediatric Respiratory Medicine</p>
Keywords:	Respiratory, Neuromuscular, Neurodisability, Costing

SCHOLARONE™
Manuscripts

1
2
3
4 **1 Healthcare Utilisation in Children with SMA Type 1 Treated with Nusinersen:**
5 **2 a single centre retrospective review**
6
7
8
9
10

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

4 Imran Ali¹ MB BS

5 *Senior House Officer*

6 Francis Gilchrist¹

7 *Consultant Respiratory Paediatrician*

8 Will Carroll¹

9 *Consultant Paediatrician*

10 John Alexander¹

11 *Consultant Paediatrician*

12 Sadie Clayton¹

13 *Consultant Nurse*

14 Richa Kulshrestha²

15 *Consultant Paediatric Neurologist*

16 Tracey Willis²

17 *Consultant Paediatric Neurologist*

18 Martin Samuels¹ MD FRCPC

19 *Consultant Respiratory Paediatrician*

20
21 Address: ¹ Children's Centre

22 Royal Stoke University Hospital

23 Stoke-on-Trent

24 Staffs

25 ST4 6QG

² The Robert Jones & Agnes Hunt Orthopaedic Hospital

Oswestry

Shropshire

SY10 7AG

26
27 Corresponding Author: Dr MP Samuels

28 GMC Reg No 2732178

29 Phone no: 07710 673965

30 Email: martin.samuels@uhnm.nhs.uk or samuels@doctors.org.uk

31
32 Word Count: 2558 (excluding references)

1
2
3 1 **Healthcare Utilisation in Children with SMA Type 1 Treated with Nusinersen: a single centre**
4 2 **retrospective review**
5
6
7 3

8 4 **Abstract:**
9

10 5 **Background:** Nusinersen has been used to treat spinal muscular atrophy type 1 (SMA1) in the UK since
11 6 2017. While initial trials showed neuromuscular benefit from treating SMA1, there is little information
12 7 on the respiratory effects of nusinersen. We aimed to look at the respiratory care, hospital utilisation
13 8 and associated costs in newly treated SMA1.
14
15
16
17
18
19 9

20
21 10 **Methods:** We reviewed the medical records of all children within the West Midlands with SMA1
22 11 treated with nusinersen at Royal Stoke University Hospital. Baseline demographics and hospital
23 12 admission data were collected including: the reason for admission, total hospital days, HDU days, PICU
24 13 days, days intubated, discharge diagnosis, doses of nusinersen and treatment complications.
25
26
27
28
29 14

30
31 15 **Results:** Eleven children (six girls) received nusinersen between May 2017 and April 2019. Their
32 16 median (range) age was 29 (7–97) months. The median (range) number of nusinersen doses per child
33 17 was 6 (4-8). All children were receiving long-term ventilatory support; this was non-invasive BiPAP in
34 18 nine and tracheostomy ventilation in two. The total number of hospital days since diagnosis was 1101
35 19 with a median (range) of 118 (7-235) days per child. This included general paediatric ward days 0 (0-
36 20 63), HDU 79 (7-173) days and PICU 13 (0-109) days per child. This equated to a median (range) of 20
37 21 (2 - 72) % of their life in hospital. The estimated cost of this care was £2.2M.
38
39
40
41
42
43
44 22

45
46 23 **Conclusion:** Patients with SMA1 treated with nusinersen spend a considerable proportion of their
47 24 early life in hospital. Parents should be counselled accordingly. These data suggest that for every 10
48 25 children started on nusinersen an extra HDU bed is required. This has a significant cost implication.
49
50
51
52 26
53
54
55
56
57
58
59
60

1 Background

2 Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder characterised by
3 progressive muscular atrophy and weakness(1). It has an incidence of 1 in 11,000 live births(2). There
4 are various subgroups of SMA classified clinically, with SMA type 1 (SMA1) accounting for
5 approximately 60% of cases, and carrying the worst prognosis(3). Until recently, SMA1 was the
6 commonest genetic disease resulting in death in infancy(4). Affected children usually present with
7 symptoms before six months of age and historically died from respiratory failure by the age of two
8 years(5).

9 SMA1 is caused by the homozygous deletion or mutation of the survival motor neuron 1 (*SMN1*) gene.
10 This results in reduced expression of the SMN protein, which is essential for the survival of motor
11 neurones in the spinal cord and brain stem(6). Inadequate expression of SMN protein causes
12 degeneration of the motor neurone which in turn causes the associated muscles to atrophy. Humans
13 have a variable number of copies of a second gene, *SMN2* which also encodes for SMN protein(6).
14 However, *SMN2* transcription in 80-90% of instances leads to production of a truncated, unstable form
15 of the protein which is non-functional. Approximately 80% of infants with SMA1 have only 1 or 2
16 copies of *SMN2* and are therefore unable to produce enough functional SMN protein to support
17 normal muscle development.

18 Nusinersen is an antisense oligonucleotide which works by binding to the *SMN2* mRNA and in order
19 to be effective it must be delivered into the cerebrospinal fluid. This binding modifies splicing of the
20 *SMN2* gene to promote increased production of functional SMN protein(7). Treatment with
21 nusinersen has the potential to transform prognosis for these children offering hope of treatment for
22 the first time. The drug has been used in the UK since early 2017. The drug costs £450,000 in the first
23 year and £225,000 per annum subsequently. For patients beginning this before November 2018, the
24 manufacturer provided it free through an Expanded Access Programme(8). NHSE provides an
25 administration cost, but not the other aspects of care for these patients. While randomised controlled
26 trials showed nusinersen improved motor function and development(7), it is unclear whether the
27 respiratory consequences produce similar benefits and thus the demands of treatment for families
28 and health economies is yet to be established.

29 Royal Stoke University Hospital (RSUH) is the regional centre for nusinersen administration in the West
30 Midlands which has a population of approximately 6 million. In March 2019 RSUH had the second
31 largest cohort of SMA1 patients in the UK. Before agreeing to act as a regional centre for nusinersen
32 delivery, we carefully considered the potential effects on children, their families and other healthcare

1 services. However, data were lacking making counselling of families and planning of service provision
2 difficult. We have carefully monitored healthcare utilisation of SMA1 children treated with nusinersen.
3 The aim of this article is to report the data on service utilisation for these children to assist families
4 and healthcare professionals.

5 **Methods**

6 Patients treated with intrathecal nusinersen at RSUH were identified from a local database. The paper
7 notes and electronic clinical records were reviewed to collect relevant data from RSUH and the child's
8 referring hospital. This included baseline demographics, age at diagnosis, details of ventilatory
9 support, feeding support, number of nusinersen doses, complications following administration and
10 details of all hospital admissions. Hospital admission data included: duration of admission, number of
11 HDU days, PICU days and intubated days. Nusinersen usually necessitated admission for one night for
12 the first dose only. All children received care in accordance to the published international guidelines
13 for the care of children with SMA(9,10). Intrathecal nusinersen was administered by appropriately
14 trained paediatricians in the PICU treatment room. In babies this was performed using local
15 anaesthetic and in toddlers using low dose opiate analgesia and / or sedation. No child has required a
16 general anaesthetic or interventional radiology.

17 **Patient and public involvement**

18 No patients were involved in setting the research question or the outcome measures. The results of
19 this study will be disseminated to patient groups such as SMA UK and MD UK.

20 **Approval and ethical considerations**

21 The HRA decision tool (<http://www.hra-decisiontools.org.uk/research>) confirmed this project was
22 audit not research and so ethical approval was not sought. The audit was approved by the
23 departmental governance lead.

24 **Results**

25 We identified eleven children (six girls) who received nusinersen through the Expanded Access
26 Program at RSUH between May 2017 and April 2019. Parents of a 12th child declined nusinersen and
27 the child died at 3 months of age. The median (range) number of nusinersen doses was 6 (4-8). Nine
28 children received non-invasive BiPAP and two children were ventilated via tracheostomy (TIV). Six
29 children had been commenced on ventilation prior to their first dose of nusinersen. Both patients
30 receiving TIV had the tracheostomy inserted before nusinersen was commenced. Two patients
31 (including one on tracheostomy ventilation) have died suddenly at home from presumed mucous

1 plugs at 12 and 16 months of age, while one other patient had a cardiorespiratory arrest and has
 2 suffered hypoxic brain injury.

3 Table 1: Characteristics of cohort

	Median	Range
Age at diagnosis (months)	16.6	9 – 53.2
Age of first dose nusinersen (months)	20.6	1– 217.2
Age at initiation of LTV 2 (months)	20.9	5.8- 92.5
Age at initiation of advanced care pathway (n= 4) (months)	54	18.1 – 179.4
Number of admissions per child*	11	1 – 25
Number of emergency admissions per child*	3	0 – 21
Number of elective admissions per child*	4	0 – 9
Hospital days per child*	84	7 – 235
General paediatric hospital days per child*	0	0 – 63
HDU days per child*	79	7 – 173
PICU days per child*	13	0 - 109

4 *Over 24 months.

5 Duration and location of admissions

6 In 24 months, the 11 children had spent a total of 1101 days in hospital. Details of the hospitalisation
 7 are summarised in Table 1.-Three children were responsible for all admissions to the general paediatric
 8 ward which occurred at their local hospital. During these admissions, the respiratory team at RSUH
 9 liaised closely with local providers to guide acute management and arranged transfer when necessary.
 10 Three children had not been admitted to PICU. Of the eight children that had, six had been intubated
 11 for a total of 38 days. The median (range) proportion of life spent in hospital was 20% (2% - 72%). This
 12 was variable with four children spending $\leq 10\%$, four 10-35% and three $>35\%$.

13 Reason for admission

14 The median age (range) for initiation of nusinersen was 35 (2 – 372) weeks. Since initiation of
 15 nusinersen the eleven children had a total of 107 hospital admissions with a median (range) per child
 16 of 11 (1-25). The commonest reason for admission was lower respiratory tract infection (n=42),
 17 followed by elective administration of intrathecal nusinersen (n=38). There were seven admissions for
 18 gastrointestinal issues, six for an elective sleep study, five for aspiration pneumonia, four for increased
 19 secretions or airway issues and three for optimisation of ventilatory support. At each admission for
 20 nusinersen the patient and family were reviewed by the paediatric palliative care team who

1 administered intrathecal treatment and assessed palliative needs. Children also received
 2 physiotherapy whilst inpatients. The physiotherapy adjuncts used by patients are listed in table 2. Four
 3 children had advanced care pathways in place. Between hospital admissions all the children were
 4 reviewed regularly in the outpatient clinic by the Paediatric Respiratory Multidisciplinary Team.

5 Table 2. Physiotherapy adjuncts that SMA1 children required

Physiotherapy Adjunct	Number (percentage) of children requiring adjunct
Saline Nebulisers	8 (72%)
Suction	11 (100%)
Percussion	9 (82%)
Cough Assist machine	5 (45%)
High Frequency chest wall oscillation vest	1 (0.9%)

6 Trends in admissions

7 Children in our cohort had the greatest requirement for hospital admission in the first 6 months
 8 following nusinersen initiation (see Figure 1). Much of this effect is driven by a tendency for children
 9 to have a long first admission (see Figure 2). Subsequent admissions tend to be shorter. The total
 10 number of hospital days for the children's first admission was 426 days with a median (range) of 20 (1
 11 -235) days per child.

12 Cost implications and impact on local services

13 A total of 762 HDU days and 248 PICU days were required by the 11 children in our cohort over two
 14 years. This equates to 2.8 days in HDU and 0.93 days in PICU per child each month. RSUH has six HDU
 15 (four acute HDU beds and two long term ventilation) and eight PICU beds. The children therefore
 16 occupied 17% of the total HDU capacity and 4.2% of the PICU capacity over the study period. Based
 17 on current estimates of £1626 per day for a HDU bed and £1785 to £3784 for a PICU bed (depending
 18 on the level of care), the additional cost of these HDU/PICU days is £2.2M(11). This is separate to the
 19 cost of the nusinersen and its administration.

20 In addition to the costs associated with in-patient care, these children frequently require care
 21 packages which incur additional community costs. These costs are likely to continue throughout the
 22 child's life. In this small cohort, we found families highly motivated to provide care for their children
 23 and no child experienced a prolonged hospital admission as a result of awaiting funding for the
 24

1
2
3 1 provision of a care package. Four children had care packages implemented: one child had 16 hours
4 2 of care a week and three of the children had over 85 hours care per week. These three children
5 3 received care seven nights a week between nine to ten hours and three days a week between five to
6 4 eight hours.
7
8
9

10 5 11 6 12 7 **Discussion**

13 8 This is the first study which accurately reports the in-patient healthcare utilisation of a cohort of
14 9 children treated with nusinersen. This information is vital for those planning hospital healthcare
15 10 services. In the first two years after diagnosis, these children spend, on average, one fifth of their early
16 11 life in hospital although there is considerable inter-individual variation. This places a significant burden
17 12 on parents and families and they should be counselled accordingly. There is a considerable impact on
18 13 hospital services, particularly on high dependency and PICU. However, not all children required PICU
19 14 admission and not all children admitted to PICU required endotracheal intubation. This involves a
20 15 substantial extra resource, in addition to the direct cost of the nusinersen. Reassuringly, the number
21 16 of hospital days has reduced as the child grows older. In our cohort, the 11 children required 762 HDU
22 17 days over 24 months. This equates to the need for an additional HDU bed for every 10 children
23 18 commenced on nusinersen.
24
25

26 19 NHSE has decided to fund nusinersen for the next five years so the numbers of SMA1 patients surviving
27 20 and treated with nusinersen will increase, along with the demand on critical care and community
28 21 services. Currently there is no ring-fenced funding for the health needs of SMA1 patients receiving
29 22 nusinersen and this is something that must be explored to provide optimal care for these patients
30 23 without affecting that of other children requiring critical care or general paediatric services. Only a
31 24 small proportion of admissions was managed wholly at the children's local hospital where expertise
32 25 in NIV is being slowly developed.
33
34

35 26 We acknowledge the limitations of this study. It includes only eleven patients treated at one centre,
36 27 although this is the second largest in the UK. The retrospective nature of the study may have
37 28 introduced bias and we did not adjust for potential confounding factors such as socioeconomic status
38 29 and co-morbidities. Given the small numbers of children in this cohort we have elected not to report
39 30 a detailed phenotype and correlation to healthcare utilisation as any observed correlations may be
40 31 spurious and open to misinterpretation. Instead, we have chosen to consider the cohort as a group as
41 32 this allows funders, clinicians and those planning healthcare services to make better informed
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 1 decisions. Estimates of the financial burden have concentrated on in-patient rather than community
4 costs and will therefore be an underestimate. We could not undertake an accurate review of
5
6 2 healthcare costs in our region for children with SMA1 prior to the introduction of nusinersen as most
7 children did not receive active treatment and died in their local hospital. A recent German study
8
9 3 estimated the total direct cost of illness for children with SMA1 to be €99,664 per year(12).

10
11
12 4 As the children grow older, there is a fall in the number of days spent in hospital. This is in part due to
13 a prolonged first admission, during which the child was stabilised and the family were trained and
14
15 5 counselled. It may also be explained by: i) a true improvement in the respiratory muscle strength of
16 these children over time, or ii) a gradual improvement in the medical care provided, or iii) an improved
17
18 6 ability of these families to cope with their medical conditions at home and in their own community or
19 iv) deaths within our cohort. Whilst an important consideration, mortality alone seems unlikely to be
20
21 7 the sole driver of this effect as only two children within the cohort have died. It may be a function of
22 all of these and we hope that the first three factors will continue to operate.
23
24 8

25 26 27 9 Conclusion

28
29 10 While the improved prognosis and life expectancy associated with nusinersen treatment is exciting
30 for children with SMA1 and their families, we remain unsure that the respiratory benefits are as great
31
32 11 as that shown for the neurological improvement in the preliminary trials. This study has highlighted
33 that such children will spend a significant amount of their life in hospital, particularly in the first
34
35 12 months after diagnosis. This places a significant burden on families and on the NHS in general. The
36 long term outcome for these children is still unknown but the trend for a reduction in hospital days as
37
38 13 the child grows older may be reassuring. Further prospective studies with larger patient numbers are
39 required to more accurately quantify the longer term health care utilisation by these children and the
40
41 14 associated financial burden.
42
43 15
44
45 16
46
47 17
48
49 18
50
51 19
52
53 20
54
55 21
56
57 22
58
59 23
60 24
25
26
27
28
29
30

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

What is already known on this topic:

Nusinersen improves prognosis and life expectancy in children with SMA 1.

Infants are now surviving with immense dependency on healthcare services.

NICE agreed in May 2019 to fund this new treatment.

What this study adds:

Children with SMA1 who receive Nusinersen have significant ongoing medical costs in addition to the cost of the drugs received.

On average this currently is more than £100,000 per patient per year in the first two years of follow up.

Associated healthcare costs reduce as time progresses and are less in the second year of life.

Confidential: For Review Only

References

1. Pearn J. Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. *Journal of medical genetics*. 1978 Dec;15(6):409–13.
2. Kolb SJ, Kissel JT. Spinal Muscular Atrophy. *Neurologic clinics*. 2015 Nov;33(4):831–46.
3. Verhaart IEC, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S, Jones CC, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. *Orphanet journal of rare diseases*. 2017 Jul 4;12(1):124–124.
4. Wirth B. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). *Hum Mutat*. 2000;15(3):228–37.
5. Park HB, Lee SM, Lee JS, Park MS, Park KI, Namgung R, et al. Survival analysis of spinal muscular atrophy type I. *Korean journal of pediatrics*. 2010 Nov;53(11):965–70.
6. Burghes AHM, Beattie CE. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? *Nature reviews Neuroscience*. 2009 Aug;10(8):597–609.
7. Finkel RS, Chiriboga CA, Vajsaar J, Day JW, Montes J, De Vivo DC, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. *Lancet*. 2016 Dec 17;388(10063):3017–26.
8. NICE project team. Nusinersen for treating spinal muscular atrophy [Internet]. NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE; 2018 [cited 2019 Nov 1]. Available from: <https://www.nice.org.uk/guidance/gid-ta10281/documents/appraisal-consultation-document>
9. Finkel RS, Mercuri E, Meyer OH, Simonds AK, Schroth MK, Graham RJ, et al. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. *Neuromuscul Disord*. 2018;28(3):197–207.
10. Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, et al. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. *Neuromuscul Disord*. 2018;28(2):103–15.
11. NHS improvement. National cost collection guidance 2019 [Internet]. NHS; 2019 [cited 2019 Apr 2]. Available from: https://improvement.nhs.uk/documents/4883/National_cost_collections_19.pdf
12. Klug C, Schreiber-Katz O, Thiele S, Schorling E, Zowe J, Reilich P, et al. Disease burden of spinal muscular atrophy in Germany. *Orphanet Journal of Rare Diseases*. 2016 May 4;11(1):58.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Figure Legend

2 Figure 1: Total hospital days per month spent by children following commencement on nusinersen.

3 Figure 2: Median length of hospital stay per admission for all children.


Confidential: For Review Only

1
2
3 1 Footnotes
4

5
6 2 Contributors: MS and JA originated the design of the study. IA collected the data and drafted the
7
8 3 manuscript. FG and MS supervised the writing. IA, FG, WC, MS, JA, SC, TW and RK revised each draft
9
10 4 for important intellectual content. All authors read and approved the final manuscript. MS had
11
12 5 primary responsibility for the final content and is the guarantor. The corresponding author (MS)
13
14 6 attests that all listed authors meet authorship criteria and that no others meeting the criteria have
15
16 7 been omitted.


17
18 8 Transparency: The manuscript's guarantor (MS) affirms that the manuscript is an honest, accurate,
19
20 9 and transparent account of the study being reported; that no important aspects of the study have
21
22 10 been omitted; and that any discrepancies from the study as planned have been explained.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



254x190mm (96 x 96 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



254x190mm (96 x 96 DPI)

BMJ Paediatrics Open

Healthcare Utilisation in Children with SMA Type 1 Treated with Nusinersen: a single centre retrospective review

Journal:	<i>BMJ Paediatrics Open</i>
Manuscript ID	bmjpo-2019-000572.R2
Article Type:	Original research
Date Submitted by the Author:	30-Oct-2019
Complete List of Authors:	<p>Ali, Imran; University Hospitals of North Midlands NHS Trust, Paediatric Respiratory Medicine</p> <p>Gilchrist, Francis; University Hospitals of North Midlands NHS Trust, Paediatric Respiratory Medicine; Keele University, Institute of Applied Clinical Science</p> <p>Carroll, William; University Hospitals of North Midlands NHS Trust, Paediatric Respiratory Medicine; Keele University, Institute of Applied Clinical Services</p> <p>Alexander, John; University Hospitals of North Midlands NHS Trust, Paediatric Respiratory Medicine</p> <p>Clayton, Sadie ; University Hospitals of North Midlands NHS Trust, Paediatric Respiratory Medicine</p> <p>Kulshrestha, Richa; Robert Jones and Agnes Hunt Orthopaedic and District Hospital NHS Trust</p> <p>Willis, Tracey; Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust</p> <p>Samuels, Martin; University Hospitals of North Midlands NHS Trust, Paediatric Respiratory Medicine</p>
Keywords:	Respiratory, Neuromuscular, Neurodisability, Costing

SCHOLARONE™
Manuscripts

1
2
3 **1 Healthcare Utilisation in Children with SMA Type 1 Treated with Nusinersen:**
4 **2 a single centre retrospective review**
5
6
7
8
9
10

11 4 Imran Ali¹ MB BS

12 *Senior House Officer*

13 6 Francis Gilchrist¹

14 *Consultant Respiratory Paediatrician*

15 8 Will Carroll¹

16 *Consultant Paediatrician*

17 10 John Alexander¹

18 *Consultant Paediatrician*

19 12 Sadie Clayton¹

20 *Consultant Nurse*

21 14 Richa Kulshrestha²

22 *Consultant Paediatric Neurologist*

23 16 Tracey Willis²

24 *Consultant Paediatric Neurologist*

25 18 Martin Samuels¹ MD FRCPCH

26 *Consultant Respiratory Paediatrician*

27 21 Address: ¹ Children's Centre

² The Robert Jones & Agnes Hunt Orthopaedic Hospital

28 Royal Stoke University Hospital Oswestry

29 Stoke-on-Trent Shropshire

30 Staffs SY10 7AG

31 ST4 6QG

32 Corresponding Author: Dr MP Samuels

33 GMC Reg No 2732178

34 Phone no: 07710 673965

35 Email: martin.samuels@uhnm.nhs.uk or samuels@doctors.org.uk

36 Word Count: 2558 (excluding references)

1
2
3 1 **Healthcare Utilisation in Children with SMA Type 1 Treated with Nusinersen: a single centre**
4 2 **retrospective review**
5
6
7 3

8 4 **Abstract:**
9

10 5 **Background:** Nusinersen has been used to treat spinal muscular atrophy type 1 (SMA1) in the UK since
11 6 2017. While initial trials showed neuromuscular benefit from treating SMA1, there is little information
12 7 on the respiratory effects of nusinersen. We aimed to look at the respiratory care, hospital utilisation
13 8 and associated costs in newly treated SMA1.
14
15
16
17
18
19 9

20
21 10 **Methods:** We reviewed the medical records of all children within the West Midlands with SMA1
22 11 treated with nusinersen at Royal Stoke University Hospital. Baseline demographics and hospital
23 12 admission data were collected including: the reason for admission, total hospital days, HDU days, PICU
24 13 days, days intubated, discharge diagnosis, doses of nusinersen and treatment complications.
25
26
27
28
29 14

30
31 15 **Results:** Eleven children (six girls) received nusinersen between May 2017 and April 2019. Their
32 16 median (range) age was 29 (7–97) months. The median (range) number of nusinersen doses per child
33 17 was 6 (4-8). All children were receiving long-term ventilatory support; this was non-invasive BiPAP in
34 18 nine and tracheostomy ventilation in two. The total number of hospital days since diagnosis was 1101
35 19 with a median (range) of 118 (7-235) days per child. This included general paediatric ward days 0 (0-
36 20 63), HDU 79 (7-173) days and PICU 13 (0-109) days per child. This equated to a median (range) of 20
37 21 (2 - 72) % of their life in hospital. The estimated cost of this care was £2.2M.
38
39
40
41
42
43
44 22

45
46 23 **Conclusion:** Patients with SMA1 treated with nusinersen spend a considerable proportion of their
47 24 early life in hospital. Parents should be counselled accordingly. These data suggest that for every 10
48 25 children started on nusinersen an extra HDU bed is required. This has a significant cost implication.
49
50
51
52 26
53
54
55
56
57
58
59
60

1 Background

2 Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder characterised by
3 progressive muscular atrophy and weakness(1). It has an incidence of 1 in 11,000 live births(2). There
4 are various subgroups of SMA classified clinically, with SMA type 1 (SMA1) accounting for
5 approximately 60% of cases, and carrying the worst prognosis(3). Until recently, SMA1 was the
6 commonest genetic disease resulting in death in infancy(4). Affected children usually present with
7 symptoms before six months of age and historically died from respiratory failure by the age of two
8 years(5).

9 SMA1 is caused by the homozygous deletion or mutation of the survival motor neuron 1 (*SMN1*) gene.
10 This results in reduced expression of the SMN protein, which is essential for the survival of motor
11 neurones in the spinal cord and brain stem(6). Inadequate expression of SMN protein causes
12 degeneration of the motor neurone which in turn causes the associated muscles to atrophy. Humans
13 have a variable number of copies of a second gene, *SMN2* which also encodes for SMN protein(6).
14 However, *SMN2* transcription in 80-90% of instances leads to production of a truncated, unstable form
15 of the protein which is non-functional. Approximately 80% of infants with SMA1 have only 1 or 2
16 copies of *SMN2* and are therefore unable to produce enough functional SMN protein to support
17 normal muscle development.

18 Nusinersen is an antisense oligonucleotide which works by binding to the *SMN2* mRNA and in order
19 to be effective it must be delivered into the cerebrospinal fluid. This binding modifies splicing of the
20 *SMN2* gene to promote increased production of functional SMN protein(7). Treatment with
21 nusinersen has the potential to transform prognosis for these children offering hope of treatment for
22 the first time. The drug has been used in the UK since early 2017. The drug costs £450,000 in the first
23 year and £225,000 per annum subsequently. For patients beginning this before November 2018, the
24 manufacturer provided it free through an Expanded Access Programme(8). NHSE provides an
25 administration cost, but not the other aspects of care for these patients. While randomised controlled
26 trials showed nusinersen improved motor function and development(7), it is unclear whether the
27 respiratory consequences produce similar benefits and thus the demands of treatment for families
28 and health economies is yet to be established.

29 Royal Stoke University Hospital (RSUH) is the regional centre for nusinersen administration in the West
30 Midlands which has a population of approximately 6 million. In March 2019 RSUH had the second
31 largest cohort of SMA1 patients in the UK. Before agreeing to act as a regional centre for nusinersen
32 delivery, we carefully considered the potential effects on children, their families and other healthcare

1 services. However, data were lacking making counselling of families and planning of service provision
2 difficult. We have carefully monitored healthcare utilisation of SMA1 children treated with nusinersen.
3 The aim of this article is to report the data on service utilisation for these children to assist families
4 and healthcare professionals.

5 **Methods**

6 Patients treated with intrathecal nusinersen at RSUH were identified from a local database. The paper
7 notes and electronic clinical records were reviewed to collect relevant data from RSUH and the child's
8 referring hospital. This included baseline demographics, age at diagnosis, details of ventilatory
9 support, feeding support, number of nusinersen doses, complications following administration and
10 details of all hospital admissions. Hospital admission data included: duration of admission, number of
11 HDU days, PICU days and intubated days. Nusinersen usually necessitated admission for one night for
12 the first dose only. All children received care in accordance to the published international guidelines
13 for the care of children with SMA(9,10). Intrathecal nusinersen was administered by appropriately
14 trained paediatricians in the PICU treatment room. In babies this was performed using local
15 anaesthetic and in toddlers using low dose opiate analgesia and / or sedation. No child has required a
16 general anaesthetic or interventional radiology.

17 **Patient and public involvement**

18 No patients were involved in setting the research question or the outcome measures. The results of
19 this study will be disseminated to patient groups such as SMA UK and MD UK.

20 **Approval and ethical considerations**

21 The HRA decision tool (<http://www.hra-decisiontools.org.uk/research>) confirmed this project was
22 audit not research and so ethical approval was not sought. The audit was approved by the
23 departmental governance lead.

24 **Results**

25 We identified eleven children (six girls) who received nusinersen through the Expanded Access
26 Program at RSUH between May 2017 and April 2019. Parents of a 12th child declined nusinersen and
27 the child died at 3 months of age. The median (range) number of nusinersen doses was 6 (4-8). Nine
28 children received non-invasive BiPAP and two children were ventilated via tracheostomy (TIV). Six
29 children had been commenced on ventilation prior to their first dose of nusinersen. Both patients
30 receiving TIV had the tracheostomy inserted before nusinersen was commenced. Two patients
31 (including one on tracheostomy ventilation) have died suddenly at home from presumed mucous

1 plugs at 12 and 16 months of age, while one other patient had a cardiorespiratory arrest and has
 2 suffered hypoxic brain injury.

3 Table 1: Characteristics of cohort

	Median	Range
Age at diagnosis (months)	16.6	9 – 53.2
Age of first dose nusinersen (months)	20.6	1– 217.2
Age at initiation of LTV 2 (months)	20.9	5.8- 92.5
Age at initiation of advanced care pathway (n= 4) (months)	54	18.1 – 179.4
Number of admissions per child*	11	1 – 25
Number of emergency admissions per child*	3	0 – 21
Number of elective admissions per child*	4	0 – 9
Hospital days per child*	84	7 – 235
General paediatric hospital days per child*	0	0 – 63
HDU days per child*	79	7 – 173
PICU days per child*	13	0 - 109

4 *Over 24 months.

5 Duration and location of admissions

6 In 24 months, the 11 children had spent a total of 1101 days in hospital. Details of the hospitalisation
 7 are summarised in Table 1.-Three children were responsible for all admissions to the general paediatric
 8 ward which occurred at their local hospital. During these admissions, the respiratory team at RSUH
 9 liaised closely with local providers to guide acute management and arranged transfer when necessary.
 10 Three children had not been admitted to PICU. Of the eight children that had, six had been intubated
 11 for a total of 38 days. The median (range) proportion of life spent in hospital was 20% (2% - 72%). This
 12 was variable with four children spending $\leq 10\%$, four 10-35% and three $>35\%$.

13 Reason for admission

14 The median age (range) for initiation of nusinersen was 35 (2 – 372) weeks. Since initiation of
 15 nusinersen the eleven children had a total of 107 hospital admissions with a median (range) per child
 16 of 11 (1-25). The commonest reason for admission was lower respiratory tract infection (n=42),
 17 followed by elective administration of intrathecal nusinersen (n=38). There were seven admissions for
 18 gastrointestinal issues, six for an elective sleep study, five for aspiration pneumonia, four for increased
 19 secretions or airway issues and three for optimisation of ventilatory support. At each admission for
 20 nusinersen the patient and family were reviewed by the paediatric palliative care team who

1 administered intrathecal treatment and assessed palliative needs. Children also received
 2 physiotherapy whilst inpatients. The physiotherapy adjuncts used by patients are listed in table 2. Four
 3 children had advanced care pathways in place. Between hospital admissions all the children were
 4 reviewed regularly in the outpatient clinic by the Paediatric Respiratory Multidisciplinary Team.

5 Table 2. Physiotherapy adjuncts that SMA1 children required

Physiotherapy Adjunct	Number (percentage) of children requiring adjunct
Saline Nebulisers	8 (72%)
Suction	11 (100%)
Percussion	9 (82%)
Cough Assist machine	5 (45%)
High Frequency chest wall oscillation vest	1 (0.9%)

6 Trends in admissions

7 Children in our cohort had the greatest requirement for hospital admission in the first 6 months
 8 following nusinersen initiation (see Figure 1). Much of this effect is driven by a tendency for children
 9 to have a long first admission (see Figure 2). Subsequent admissions tend to be shorter. The total
 10 number of hospital days for the children's first admission was 426 days with a median (range) of 20 (1
 11 -235) days per child.

12 Cost implications and impact on local services

13 A total of 762 HDU days and 248 PICU days were required by the 11 children in our cohort over two
 14 years. This equates to 2.8 days in HDU and 0.93 days in PICU per child each month. RSUH has six HDU
 15 (four acute HDU beds and two long term ventilation) and eight PICU beds. The children therefore
 16 occupied 17% of the total HDU capacity and 4.2% of the PICU capacity over the study period. Based
 17 on current estimates of £1626 per day for a HDU bed and £1785 to £3784 for a PICU bed (depending
 18 on the level of care), the additional cost of these HDU/PICU days is £2.2M(11). This is separate to the
 19 cost of the nusinersen and its administration.

20 In addition to the costs associated with in-patient care, these children frequently require care
 21 packages which incur additional community costs. These costs are likely to continue throughout the
 22 child's life. In this small cohort, we found families highly motivated to provide care for their children
 23 and no child experienced a prolonged hospital admission as a result of awaiting funding for the
 24 provision of a care package. Four children had care packages implemented: one child had 16 hours
 25

1
2
3 1 of care a week and three of the children had over 85 hours care per week. These three children
4 2 received care seven nights a week between nine to ten hours and three days a week between five to
5 3 eight hours. One with a large care package had tracheostomy ventilation, but the parents of the
6 4 other child with tracheostomy declined a care package.
7
8
9 5

6 **Discussion**

7 This is the first study which accurately reports the in-patient healthcare utilisation of a cohort of
8 children treated with nusinersen. This information is vital for those planning hospital healthcare
9 services. In the first two years after diagnosis, these children spend, on average, one fifth of their early
10 life in hospital although there is considerable inter-individual variation. This places a significant burden
11 on parents and families and they should be counselled accordingly. There is a considerable impact on
12 hospital services, particularly on high dependency and PICU. However, not all children required PICU
13 admission and not all children admitted to PICU required endotracheal intubation. This involves a
14 substantial extra resource, in addition to the direct cost of the nusinersen. Reassuringly, the number
15 of hospital days has reduced as the child grows older. In our cohort, the 11 children required 762 HDU
16 days over 24 months. This equates to the need for an additional HDU bed for every 10 children
17 commenced on nusinersen.

18 NHSE has decided to fund nusinersen for the next five years so the numbers of SMA1 patients surviving
19 and treated with nusinersen will increase, along with the demand on critical care and community
20 services. Currently there is no ring-fenced funding for the health needs of SMA1 patients receiving
21 nusinersen and this is something that must be explored to provide optimal care for these patients
22 without affecting that of other children requiring critical care or general paediatric services. Only a
23 small proportion of admissions was managed wholly at the children's local hospital where expertise
24 in NIV is being slowly developed.

25 We acknowledge the limitations of this study. It includes only eleven patients treated at one centre,
26 although this is the second largest in the UK. The retrospective nature of the study may have
27 introduced bias and we did not adjust for potential confounding factors such as socioeconomic status
28 and co-morbidities. Given the small numbers of children in this cohort we have elected not to report
29 a detailed phenotype and correlation to healthcare utilisation as any observed correlations may be
30 spurious and open to misinterpretation. Instead, we have chosen to consider the cohort as a group as
31 this allows funders, clinicians and those planning healthcare services to make better informed
32 decisions. Estimates of the financial burden have concentrated on in-patient rather than community
33 costs and will therefore be an underestimate. We could not undertake an accurate review of

1
2
3 1 healthcare costs in our region for children with SMA1 prior to the introduction of nusinersen as most
4 2 children did not receive active treatment and died in their local hospital. A recent German study
5 3 estimated the total direct cost of illness for children with SMA1 to be €99,664 per year⁽¹²⁾.
6
7
8

9 4 As the children grow older, there is a fall in the number of days spent in hospital. This is in part due to
10 5 a prolonged first admission, during which the child was stabilised and the family were trained and
11 6 counselled. It may also be explained by: i) a true improvement in the respiratory muscle strength of
12 7 these children over time, or ii) a gradual improvement in the medical care provided, or iii) an improved
13 8 ability of these families to cope with their medical conditions at home and in their own community or
14 9 iv) deaths within our cohort. Whilst an important consideration, mortality alone seems unlikely to be
15 10 the sole driver of this effect as only two children within the cohort have died. It may be a function of
16 11 all of these and we hope that the first three factors will continue to operate.
17
18
19
20
21

22 Conclusion

23
24
25 13 While the improved prognosis and life expectancy associated with nusinersen treatment is exciting
26 14 for children with SMA1 and their families, we remain unsure that the respiratory benefits are as great
27 15 as that shown for the neurological improvement in the preliminary trials. This study has highlighted
28 16 that such children will spend a significant amount of their life in hospital, particularly in the first
29 17 months after diagnosis. This places a significant burden on families and on the NHS in general. The
30 18 long term outcome for these children is still unknown but the trend for a reduction in hospital days as
31 19 the child grows older may be reassuring. Further prospective studies with larger patient numbers are
32 20 required to more accurately quantify the longer term health care utilisation by these children and the
33 21 associated financial burden.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 What is already known on this topic:

2 Nusinersen improves prognosis and life expectancy in children with SMA 1.

3 Infants are now surviving with immense dependency on healthcare services.

4 NICE agreed in May 2019 to fund this new treatment.

5

6 What this study adds:

7 Children with SMA1 who receive Nusinersen have significant ongoing medical costs in addition to the
8 cost of the drugs received.

9 On average this currently is more than £100,000 per patient per year in the first two years of follow
10 up.

11 Associated healthcare costs reduce as time progresses and are less in the second year of life.

12

13

14

15

16

17

18

19

20

21

22

23

24 References

- 1 1. Pearn J. Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. *Journal of medical genetics*. 1978 Dec;15(6):409–13.
- 2 2. Kolb SJ, Kissel JT. Spinal Muscular Atrophy. *Neurologic clinics*. 2015 Nov;33(4):831–46.
- 3 3. Verhaart IEC, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S, Jones CC, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. *Orphanet journal of rare diseases*. 2017 Jul 4;12(1):124–124.
- 4 4. Wirth B. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). *Hum Mutat*. 2000;15(3):228–37.
- 5 5. Park HB, Lee SM, Lee JS, Park MS, Park KI, Namgung R, et al. Survival analysis of spinal muscular atrophy type I. *Korean journal of pediatrics*. 2010 Nov;53(11):965–70.
- 6 6. Burghes AHM, Beattie CE. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? *Nature reviews Neuroscience*. 2009 Aug;10(8):597–609.
- 7 7. Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. *Lancet*. 2016 Dec 17;388(10063):3017–26.
- 8 8. NICE project team. Nusinersen for treating spinal muscular atrophy [Internet]. NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE; 2018 [cited 2019 Nov 1]. Available from: <https://www.nice.org.uk/guidance/gid-ta10281/documents/appraisal-consultation-document>
- 9 9. Finkel RS, Mercuri E, Meyer OH, Simonds AK, Schroth MK, Graham RJ, et al. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. *Neuromuscul Disord*. 2018;28(3):197–207.
- 10 10. Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, et al. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. *Neuromuscul Disord*. 2018;28(2):103–15.
- 11 11. NHS improvement. National cost collection guidance 2019 [Internet]. NHS; 2019 [cited 2019 Apr 2]. Available from: https://improvement.nhs.uk/documents/4883/National_cost_collections_19.pdf
- 12 12. Klug C, Schreiber-Katz O, Thiele S, Schorling E, Zowe J, Reilich P, et al. Disease burden of spinal muscular atrophy in Germany. *Orphanet Journal of Rare Diseases*. 2016 May 4;11(1):58.

35 Figure Legend

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Figure 1: Total hospital days per month spent by children following commencement on nusinersen.

2 Figure 2: Median length of hospital stay per admission for all children.

3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57


Confidential: For Review Only

23 Footnotes

1
2
3 1 Contributors: MS and JA originated the design of the study. IA collected the data and drafted the
4 2 manuscript. FG and MS supervised the writing. IA, FG, WC, MS, JA, SC, TW and RK revised each draft
5 3 for important intellectual content. All authors read and approved the final manuscript. MS had
6 4 primary responsibility for the final content and is the guarantor. The corresponding author (MS)
7 5 attests that all listed authors meet authorship criteria and that no others meeting the criteria have
8 6 been omitted.


9 7 Transparency: The manuscript's guarantor (MS) affirms that the manuscript is an honest, accurate,
10 8 and transparent account of the study being reported; that no important aspects of the study have
11 9 been omitted; and that any discrepancies from the study as planned have been explained.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



254x190mm (96 x 96 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



254x190mm (96 x 96 DPI)